智通财经网·2026-01-22 11:32Core Viewpoint - Fosun Pharma plans to spin off its subsidiary, Fosun Antigen, and list it on the Hong Kong Stock Exchange, with an initial offering size not exceeding 25% of the expanded total share capital post-issuance [1][2] Group 1: Spin-off Details - The proposed listing will involve H-shares with a par value of RMB 1.00 per share [1] - The initial offering will include an overallotment option of up to 15% of the initial issuance size [1] - The global offering will target institutional investors, enterprises, and qualified domestic investors, including those from Hong Kong, Macau, Taiwan, and other foreign regions [1] Group 2: Business Overview - Fosun Pharma is a global healthcare group driven by innovation, operating in pharmaceuticals, medical devices, diagnostics, and healthcare services [1] - Fosun Antigen focuses on vaccine research, production, and sales, utilizing various technological platforms [1] Group 3: Financial Implications - Post-spin-off, Fosun Antigen will remain a subsidiary, and its financial performance will still be reflected in Fosun Pharma's consolidated financial statements [2] - Short-term net profit contributions from Fosun Antigen may decrease, but long-term financing capabilities and operational scale are expected to improve, enhancing overall competitiveness and brand recognition [2] - The spin-off will not involve the issuance of new shares and will not affect the company's equity structure [2]